Letrozole in Metastatic Breast Cancer in Combination With Chemotherapy

Exclusion Criteria

• •Age ≥ 65 years
• •Performance status ≤ 2 (World Health Organization)
• •Estimated life expectancy under therapy of at least 3 months
• •Estrogen-/progesterone-receptor status positive or unknown
• •Signed informed consent
• •Prior chemo- or hormone therapy for metastatic breast cancer; prior therapy with aromatase inhibitors in the adjuvant setting
• •Disease-free interval after adjuvant therapy \< 1 year
• •Clinical signs of central nervous system metastases
• •Renal, bone marrow, or liver insufficiency
• •Severe coronary heart disease, cardiac insufficiency or other severe concomitant internal diseases